9M 2023 Financial Overview
9M 2023: APPENDIX
Brintellix/Trintellix
1,500
1,200
900
600
300
Brintellix/Trintellix revenue
(Quarterly DKKm)
Brintellix®
vortioxetine
Trintellix
vortioxetine
Brintellix/Trintellix revenue
(9M - DKKm)
4,000
-7%
reported
3,000
2,000
1,000
+1%
reported
0
0
Q3.20
Q3.21
Q3.22
Q3.23
9M 2020 9M 2021 9M 2022
9M 2023
39
United States
Europe
International Markets
Unless otherwise stated, growth rates are at CER. Trintellix was approved by FDA September 2013, by MHLW Japan September 2019 and
Brintellix by EMA December 2013
Comments
.
Grew 4% (+1% reported) and reached DKK
3.2bn in 9M 2023
Continued robust demand in most markets
Brintellix/Trintellix franchise protected for
several years:
Patents issued lasting to March 2032
Composition of matter patent expires in
December 2026 (including extensions)View entire presentation